Jazz Pharmaceuticals Plc Stock Price To Earning
| J7Z Stock | EUR 116.85 1.15 0.97% |
Jazz Pharmaceuticals plc fundamentals help investors to digest information that contributes to Jazz Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Jazz Stock. The fundamental analysis module provides a way to measure Jazz Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jazz Pharmaceuticals stock.
Jazz |
Jazz Pharmaceuticals plc Company Price To Earning Analysis
Jazz Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Jazz Pharmaceuticals Price To Earning | 15.29 X |
Most of Jazz Pharmaceuticals' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jazz Pharmaceuticals plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, Jazz Pharmaceuticals plc has a Price To Earning of 15.29 times. This is 40.83% lower than that of the Healthcare sector and 210.14% higher than that of the Biotechnology industry. The price to earning for all Germany stocks is 46.76% higher than that of the company.
Jazz Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jazz Pharmaceuticals' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jazz Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jazz Pharmaceuticals by comparing valuation metrics of similar companies.Jazz Pharmaceuticals is currently under evaluation in price to earning category among its peers.
Jazz Fundamentals
| Return On Equity | -0.0056 | |||
| Return On Asset | 0.053 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 13.72 B | |||
| Shares Outstanding | 62.97 M | |||
| Shares Owned By Insiders | 2.52 % | |||
| Shares Owned By Institutions | 93.17 % | |||
| Price To Earning | 15.29 X | |||
| Price To Book | 3.49 X | |||
| Price To Sales | 2.60 X | |||
| Revenue | 3.09 B | |||
| Gross Profit | 2.88 B | |||
| EBITDA | 718.41 M | |||
| Net Income | (329.67 M) | |||
| Cash And Equivalents | 833.95 M | |||
| Cash Per Share | 14.72 X | |||
| Total Debt | 6.02 B | |||
| Debt To Equity | 64.50 % | |||
| Current Ratio | 3.15 X | |||
| Book Value Per Share | 43.65 X | |||
| Cash Flow From Operations | 778.51 M | |||
| Earnings Per Share | (0.26) X | |||
| Price To Earnings To Growth | 3.86 X | |||
| Target Price | 208.5 | |||
| Number Of Employees | 3.2 K | |||
| Beta | 0.71 | |||
| Market Capitalization | 8.38 B | |||
| Total Asset | 12.3 B | |||
| Z Score | 0.6 | |||
| Net Asset | 12.3 B |
About Jazz Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jazz Pharmaceuticals plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jazz Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jazz Pharmaceuticals plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Jazz Stock
When determining whether Jazz Pharmaceuticals plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Jazz Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Jazz Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Jazz Pharmaceuticals Plc Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..